The authors concluded that, in apparently healthy persons with elevated C-reactive protein levels,
rosuvastatin (Crestor) significantly reduced the incidence of major cardiovascular events.
Their much-publicized claim, that this statin lowers the risk of heart attack by approximately one half, is technically correct though highly misleading. The reported annual incidence of coronary events was 37 people in 10,000 (controls) and 17 people in 10,000 (treated).